FDA-approved, Cybin-sponsored clinicial trial to measure ketamine ’s impact on the brain via Kernel Flow neuroimaging helmet

This study of ketamine’s psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding,” said Dr. Alex Belser, Cybin’s Chief Clinical Officer… “Quantitatively measuring the brain within the context of a psychedelic experience is a promising frontier,” said Bryan Johnson, founder and Chief Executive Officer of Kernel. “With Kernel Flow, Cybin’s researchers can start putting numbers and quantification to subjective states of mind, including altered ones.” Kernel Flow uses pulsed light instead of continuous wave light to increase measured brain information. In contrast with electroencephalography (“EEG”) electrodes that usually require gel on the head or functional magnetic resonance imaging (“fMRI”) studies that require a participant to lie in a scanner, Kernel Flow is easily wearable. The entire system is the size and look of a bicycle helmet and could, in the future, be more broadly used for neuroscientific or physiological studies of brain activity during psychedelic use. News in Context: Kernel raises $53 million to ease access to rich neural data and market Neuroscience as a Service (NaaS) Beacon Biosignals raises $27M to scale EEG, AI-based neurobiomarker discovery platform Machine-learning study finds EEG brain signatures that predict response to antidepressant treatments Cumulus Neuroscience raises $8.3M to develop EEG-based wireless ‘Fitbit for the brain’ New re...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Brain/ Mental Health Technology & Innovation Brain-Imaging Cerebral Cortex Clinical-Trial Consciousness Cybin drug development FDA human cognition Kernel ketamine neuroimaging neuroimaging helmet neurological activity placebo Source Type: blogs